Global API sourcing simplified
We connect API buyers and suppliers worldwide with speed, trust, and full transparency.

Filters

Filters
Filter
Custom request?
Type
Production region
Qualifications
Show more

Albaconazole API Manufacturers & Suppliers

1 verified results
When insight is your advantage
Full data, full access, full negotiation power
Total market transparency Total market transparency
|
Supplier trade data access Supplier trade data access
|
Buyer / supplier flow comparison Buyer / supplier flow comparison

Commercial-scale Suppliers

Distributor
Produced in  World
|

Employees: 50

|
Audit Report: Currently Eurofins has no report for this supplier. Contact them to let them know you're interested!
Certifications: GMP
|
CEP
|
USDMF
|
MSDS
|
ISO9001

All certificates

GMP
CEP
USDMF
MSDS
ISO9001
CoA
Take control of your API sourcing
Submit a Special Inquiry and have Pharmaoffer activate verified suppliers.
Get full market intelligence report
Get full market intelligence report
€399,-
All Albaconazole data. Full access. Full negotiation power
When insight is your advantage
Full data, full access, full negotiation power
Total market transparency Total market transparency
|
Supplier trade data access Supplier trade data access
|
Buyer / supplier flow comparison Buyer / supplier flow comparison
Trusted by 30,000+ registered pharma professionals:
Reach multinationals, SMEs, compounding pharmacies & more!
Procaps
Pfizer
Reckitt
Sanofi
Blau
Abbvie

Albaconazole | CAS No: 187949-02-6 | GMP-certified suppliers

A medication that targets fungal infections such as onychomycosis, providing antifungal efficacy through azole-class activity, currently in investigational development.

Therapeutic categories

Anti-Infective AgentsAntifungal AgentsAzole AntifungalsHeterocyclic Compounds, Fused-RingStereoisomerismTriazoles
Generic name
Albaconazole
Molecule type
small molecule
CAS number
187949-02-6
DrugBank ID
DB12073
Approval status
Investigational drug

Product Snapshot

  • Albaconazole is a synthetic oral small molecule antifungal agent
  • Its primary therapeutic use is the treatment of fungal infections
  • Currently, albaconazole is in the investigational stage and has not received approval from major regulatory agencies such as FDA or EMA

Clinical Overview

Albaconazole (CAS number 187949-02-6) is an investigational antifungal agent belonging to the azole class of compounds. Structurally, albaconazole is classified as a quinazoline derivative, characterized by a fused bicyclic aromatic ring system composed of a benzene ring and a pyrimidine ring. It also contains a triazole moiety, which is typical among azole antifungals.

Albaconazole has been primarily studied in the context of onychomycosis, a fungal infection of the nails, although it is not currently approved for any formal clinical indications. As an azole antifungal, it is anticipated to act by inhibiting fungal cytochrome P450-dependent 14α-lanosterol demethylase, an enzyme critical for ergosterol biosynthesis in fungal cell membranes. However, specific pharmacodynamic parameters and detailed mechanistic data for albaconazole have not been publicly disclosed.

Data on absorption, distribution, metabolism, and excretion (ADME) characteristics for albaconazole remain limited due to its investigational status. Generally, azole antifungals exhibit variable oral bioavailability and tend to undergo hepatic metabolism primarily via cytochrome P450 enzymes. Safety and toxicity profiles for albaconazole have not been fully established, but azole class-related concerns include potential hepatotoxicity, drug-drug interactions, and effects on cardiac electrophysiology, which warrant careful evaluation in clinical development.

No marketed pharmaceutical products containing albaconazole are currently available. Research remains at the developmental stage with continued evaluation in clinical trials for antifungal efficacy and safety.

For formulation scientists and procurement professionals, sourcing albaconazole API requires attention to stringent quality attributes, including purity, stereochemical integrity, and compliance with good manufacturing practices (GMP). Reliable suppliers must provide comprehensive documentation to support regulatory submissions and ensure batch-to-batch consistency in investigational and potential commercial manufacturing.

Identification & chemistry

Generic name Albaconazole
Molecule type Small molecule
CAS 187949-02-6
UNII YDW24Y8IAB
DrugBank ID DB12073

Formulation & handling

  • Albaconazole is a small molecule with low aqueous solubility, indicating formulation challenges for oral bioavailability.
  • The compound’s moderate lipophilicity (LogP 2.82) suggests potential for membrane permeability and suitability for oral administration.
  • Stability data is limited; careful handling under controlled conditions is recommended to preserve compound integrity.

Regulatory status

Albaconazole is a type of Anti-infective Agents


Anti-infective agents are a vital category of pharmaceutical active pharmaceutical ingredients (APIs) used in the treatment of various infectious diseases. These agents play a crucial role in combating bacterial, viral, fungal, and parasitic infections. The demand for effective anti-infective APIs has grown significantly due to the increasing prevalence of drug-resistant microorganisms.

Anti-infective APIs encompass a wide range of substances, including antibiotics, antivirals, antifungals, and antiparasitics. Antibiotics are particularly important in fighting bacterial infections and are further categorized into different classes based on their mode of action and target bacteria. Antivirals are designed to inhibit viral replication and are essential in the treatment of viral infections such as influenza and HIV. Antifungals combat fungal infections, while antiparasitics are used to eliminate parasites that cause diseases like malaria and helminthiasis.

The development and production of high-quality anti-infective APIs require stringent manufacturing processes and adherence to regulatory standards. Pharmaceutical companies invest heavily in research and development to discover new and more effective anti-infective agents. Additionally, ensuring the safety, efficacy, and stability of these APIs is of utmost importance.

The global market for anti-infective APIs is driven by factors such as the rising incidence of infectious diseases, the emergence of new and drug-resistant pathogens, and the growing demand for improved healthcare infrastructure. Continuous advancements in pharmaceutical technology and the development of innovative drug delivery systems further contribute to the expansion of this market.

In conclusion, anti-infective agents are a critical category of pharmaceutical APIs that play a pivotal role in treating infectious diseases. Their effectiveness in combating various types of infections makes them essential components in the arsenal of modern medicine.

Albaconazole API manufacturers & distributors

Compare qualified Albaconazole API suppliers worldwide. We currently have 1 companies offering Albaconazole API, with manufacturing taking place in 1 different countries. Use the table below to review supplier type, countries of origin, certifications, product portfolio and GMP audit availability.

SupplierTypeCountryProduct originCertificationsPortfolio
Distributor
Germany World CEP, CoA, GMP, GDP, MSDS, USDMF243 products

When sending a request, specify which Albaconazole API quality you need: for example EP (Ph. Eur.), USP, JP, BP, or another pharmacopoeial standard, as well as the required grade (base, salt, micronised, specific purity, etc.).

Use the list above to find high-quality Albaconazole API suppliers. For example, you can select GMP, FDA or ISO certified suppliers. Visit our help page to learn more about sourcing APIs via Pharmaoffer.